Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amphastar Pharmaceuticals Inc (AMPH) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance

Amphastar Pharmaceuticals IncTrade
Direxion Daily S&P 500 Bull 3X SharesTrade

Price performance (Past 24H)

Key statistics

Amphastar Pharmaceuticals Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.78 (market cap $868.62M), while Direxion Daily S&P 500 Bull 3X Shares trades at $295.3. The key difference: Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

AMPHSPXL
Market Cap
$868.62M
Sector
HealthLeveraged / Inverse
52-Week High
$30.81$296.39
52-Week Low
$16.87$170.20
Enterprise Value
$1.27B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amphastar Pharmaceuticals Inc

AMPH trades at $19.87, down 2.19% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.91, beating expectations, but missed in Q4 2025 and Q1 2026. Revenue for 2025 was $719.89M with a net income margin of 10.76%, while valuation ratios like P/E of 12.08 and EV/EBITDA of 6.57 suggest reasonable pricing. Recent news highlights growth from new product launches and ongoing FDA compliance efforts.

The outlook is mixed with growth opportunities from proprietary drugs and biosimilars, but risks include regulatory scrutiny and earnings volatility. Analyst sentiment is cautious with 25% buy ratings, reflecting concerns over execution and market pressures. Investors should weigh solid cash flow generation against competitive and regulatory headwinds for balanced exposure.

Direxion Daily S&P 500 Bull 3X Shares

SPXL trades at $295.71, down 0.16% with a bullish technical outlook supported by moving averages. The stock shows strong momentum indicators with ADX signaling trend strength while RSI levels suggest potential overbought conditions. Recent news highlights S&P 500 reaching record highs with JPMorgan raising its 2026 target to 8,000, citing AI-driven earnings strength and corporate performance.

The leveraged ETF benefits from strong market momentum but faces valuation concerns with the S&P 500 at historically high Shiller P/E ratios. Key risks include market volatility ahead of inflation reports and potential profit-taking near resistance levels. The AI investment theme provides growth catalysts, though elevated valuations warrant caution for new positions.

Returns comparison

Trailing returns across standard periods

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH

About Direxion Daily S&P 500 Bull 3X Shares

SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.

Read more on SPXL